ACADIA Pharmaceuticals (MEX:ACAD) Shares Outstanding (EOP): 171 Mil (As of Mar. 2026)


MEX:ACAD ACADIA Pharmaceuticals Inc MEX:ACAD
73 GF Score
Price MXN362.00
GF Value MXN357.71
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is ACADIA Pharmaceuticals Shares Outstanding (EOP)?

ACADIA Pharmaceuticals MEX:ACAD 73 Shares Outstanding (EOP) is 171 Mil as of Mar. 2026. GuruFocus rates MEX:ACAD with a GF Score™ of 73/100 and a GF Value™ of MXN357.71 (Fairly Valued). The stock has 9 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. ACADIA Pharmaceuticals's shares outstanding for the quarter that ended in Mar. 2026 was 171 Mil.

ACADIA Pharmaceuticals's quarterly shares outstanding increased from Dec. 2025 (170 Mil) to Mar. 2026 (171 Mil). It means ACADIA Pharmaceuticals issued new shares from Dec. 2025 to Mar. 2026 .

ACADIA Pharmaceuticals's annual shares outstanding increased from Dec. 2024 (167 Mil) to Dec. 2025 (170 Mil). It means ACADIA Pharmaceuticals issued new shares from Dec. 2024 to Dec. 2025 .


ACADIA Pharmaceuticals  (MEX:ACAD) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


ACADIA Pharmaceuticals Shares Outstanding (EOP) Related Terms


ACADIA Pharmaceuticals Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for ACADIA Pharmaceuticals's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACADIA Pharmaceuticals Shares Outstanding (EOP) Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 161.01 162.07 164.65 166.71 170.31

ACADIA Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 167.12 168.61 169.15 170.31 171.09

MEX:ACAD vs EWTX, CRNX, VKTX: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, ACADIA Pharmaceuticals's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ACADIA Pharmaceuticals Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where ACADIA Pharmaceuticals's Shares Outstanding (EOP) falls into.


MEX:ACAD
73GF Score
ACADIA Pharmaceuticals Inc MEX:ACAD
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ACADIA Pharmaceuticals Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 171 Mil mean?
ACADIA Pharmaceuticals (MEX:ACAD) has a Shares Outstanding (EOP) of 171 Mil as of Mar. 2026. The total shares a company has outstanding, at period-end. View historical data on ACADIA Pharmaceuticals and its competitors.
Is ACADIA Pharmaceuticals' Shares Outstanding (EOP) too high?
ACADIA Pharmaceuticals' current Shares Outstanding (EOP) is 171 Mil. Overall, ACADIA Pharmaceuticals has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Shares Outstanding (EOP) compare to EWTX and CRNX?
ACADIA Pharmaceuticals' Shares Outstanding (EOP) of 171 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on ACADIA Pharmaceuticals and its competitors. ACADIA Pharmaceuticals's current Shares Outstanding (EOP) is 171 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (MEX:ACAD) is currently considered Fairly Valued. The stock's GF Value™ is MXN357.71, compared to a current price of MXN362.00 — trading 1.2% above its estimated fair value. The current Shares Outstanding (EOP) is 171 Mil. ACADIA Pharmaceuticals' overall GF Score™ is 73/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For ACADIA Pharmaceuticals (MEX:ACAD), the current Shares Outstanding (EOP) is 171 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACADIA Pharmaceuticals (MEX:ACAD) Overvalued in 2026?

Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued. The current stock price of MXN362.00 is trading 1.2% above its estimated GF Value™ of MXN357.71. GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.

Key valuation signals for MEX:ACAD:

  • Shares Outstanding (EOP): 171 Mil
  • GF Value™: MXN357.71 vs. price of MXN362.00 (1.2% above fair value)
  • GF Score™: 73/100 with 9 warning signs

No single metric tells the full story. See the MEX:ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ACADIA Pharmaceuticals Business Description

Other Exchanges ACAD:USADR6:Germany
Address 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
73GF Score

Get the complete analysis for MEX:ACAD

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN362.00
Price
MXN357.71
GF Value